Home LiteratureArticle Details
PMID: 12760879 Published · ppublish English Journal Article

RNA III inhibiting peptide inhibits in vivo biofilm formation by drug-resistant Staphylococcus aureus.

Antimicrobial agents and chemotherapy ·Vol. 47 ·No. 6 ·2003-06-00 ·Pages 1979-83

Giacometti A, Cirioni O, Gov Y, Ghiselli R, Del Prete MS, Mocchegiani F, Saba V, Orlando F, Scalise G, Balaban N, Dell'Acqua G

Abstract

Staphylococcus aureus is a prevalent cause of bacterial infections associated with indwelling medical devices. RNA III inhibiting peptide (RIP) is known to inhibit S. aureus pathogenesis by disrupting quorum-sensing mechanisms. RIP was tested in the present study for its ability to inhibit S. aureus biofilm formation in a rat Dacron graft model. The activity of RIP was synergistic with those of antibiotics for the complete prevention of drug-resistant S. aureus infections.

MeSH Terms
Animals Anti-Bacterial Agents/pharmacology Antibiotic Prophylaxis Biofilms/drug effects,growth & development Cell Communication/drug effects Colony Count, Microbial Drug Synergism Male Microbial Sensitivity Tests Oligopeptides/pharmacology Polyethylene Terephthalates Prostheses and Implants/microbiology Rats Rats, Wistar Staphylococcal Infections/drug therapy Staphylococcus aureus/drug effects,growth & development
Chemicals
Anti-Bacterial Agents Oligopeptides Polyethylene Terephthalates RNAIII inhibiting peptide
Authors & Affiliations
11 authors, click to expand affiliations / ORCID
Giacometti Andrea
Institute of Infectious Diseases and Public Health, Ancona, Italy.
Cirioni Oscar
Gov Yael
Ghiselli Roberto
Del Prete Maria Simona
Mocchegiani Federico
Saba Vittorio
Orlando Fiorenza
Scalise Giorgio
Balaban Naomi
Dell'Acqua Giorgio
References (29)
29 references, click to expand
  1. RNAIII inhibiting peptide (RIP) inhibits agr-regulated toxin production.
    Peptides. 2001 Oct;22(10):1621-7 PMID: 11587790
  2. RNAIII inhibiting peptide (RIP), a global inhibitor of Staphylococcus aureus pathogenesis: structure and function analysis.
    Peptides. 2001 Oct;22(10):1609-20 PMID: 11587789
  3. Prevention of Staphylococcus aureus biofilm on dialysis catheters and adherence to human cells.
    Kidney Int. 2003 Jan;63(1):340-5 PMID: 12472801
  4. Induction and inhibition of Pseudomonas aeruginosa quorum sensing by synthetic autoinducer analogs.
    Chem Biol. 2003 Jan;10(1):81-9 PMID: 12573701
  5. Use of the quorum-sensing inhibitor RNAIII-inhibiting peptide to prevent biofilm formation in vivo by drug-resistant Staphylococcus epidermidis.
    J Infect Dis. 2003 Feb 15;187(4):625-30 PMID: 12599079
  6. Prophylactic antibiotics prevent bacterial biofilm graft infection.
    J Surg Res. 1992 Feb;52(2):101-5 PMID: 1346815
  7. The critical relationship of antibiotic dose and bacterial contamination in experimental infection.
    J Surg Res. 1992 Feb;52(2):127-30 PMID: 1740934
  8. Synthesis of staphylococcal virulence factors is controlled by a regulatory RNA molecule.
    EMBO J. 1993 Oct;12(10):3967-75 PMID: 7691599
  9. Studies on the duration of antibiotic administration for surgical prophylaxis.
    Am Surg. 1997 Jan;63(1):59-62 PMID: 8985073
  10. Bacterial interference caused by autoinducing peptide variants.
    Science. 1997 Jun 27;276(5321):2027-30 PMID: 9197262
  11. Antibiotic-resistant gram-positive cocci: implications for surgical practice.
    World J Surg. 1998 Feb;22(2):118-26 PMID: 9451926
  12. Quorum sensing: potential means of treating gram-negative infections?
    Lancet. 1998 Mar 21;351(9106):848-9 PMID: 9525356
  13. The involvement of cell-to-cell signals in the development of a bacterial biofilm.
    Science. 1998 Apr 10;280(5361):295-8 PMID: 9535661
  14. Autoinducer of virulence as a target for vaccine and therapy against Staphylococcus aureus.
    Science. 1998 Apr 17;280(5362):438-40 PMID: 9545222
  15. Transmembrane topology and histidine protein kinase activity of AgrC, the agr signal receptor in Staphylococcus aureus.
    Mol Microbiol. 1998 May;28(3):655-62 PMID: 9632266
  16. Coagulase-negative staphylococci: role as pathogens.
    Annu Rev Med. 1999;50:223-36 PMID: 10073274
  17. Bacterial biofilms: a common cause of persistent infections.
    Science. 1999 May 21;284(5418):1318-22 PMID: 10334980
  18. Staphylococcus aureus bacteremia in patients undergoing hemodialysis.
    Semin Dial. 2000 Jan-Feb;13(1):23-9 PMID: 10740668
  19. Prevention of diseases caused by Staphylococcus aureus using the peptide RIP.
    Peptides. 2000 Sep;21(9):1301-11 PMID: 11072116
  20. Antistaphylococcal (MSSA, MRSA, MSSE, MRSE) antibiotics.
    Med Clin North Am. 2001 Jan;85(1):1-17 PMID: 11190346
  21. Regulation of Staphylococcus aureus pathogenesis via target of RNAIII-activating Protein (TRAP).
    J Biol Chem. 2001 Jan 26;276(4):2658-67 PMID: 11160124
  22. Designing surfaces that kill bacteria on contact.
    Proc Natl Acad Sci U S A. 2001 May 22;98(11):5981-5 PMID: 11353851
  23. Functional study of antibodies against a fibrogenin-binding protein in Staphylococcus epidermidis adherence to polyethylene catheters.
    J Infect Dis. 2001 Jul 1;184(1):52-5 PMID: 11398109
  24. Antimicrobial effects of positively charged surfaces on adhering Gram-positive and Gram-negative bacteria.
    J Antimicrob Chemother. 2001 Jul;48(1):7-13 PMID: 11418507
  25. Infectious complications of the hemodialysis access.
    Kidney Int. 2001 Jul;60(1):1-13 PMID: 11422731
  26. Detection of differential gene expression in biofilm-forming versus planktonic populations of Staphylococcus aureus using micro-representational-difference analysis.
    Appl Environ Microbiol. 2001 Jul;67(7):2958-65 PMID: 11425708
  27. Antibiotic resistance of bacteria in biofilms.
    Lancet. 2001 Jul 14;358(9276):135-8 PMID: 11463434
  28. Prophylaxis against Staphylococcus aureus vascular graft infection with mupirocin-soaked, collagen-sealed dacron.
    J Surg Res. 2001 Aug;99(2):316-20 PMID: 11469904
  29. Biofilms: survival mechanisms of clinically relevant microorganisms.
    Clin Microbiol Rev. 2002 Apr;15(2):167-93 PMID: 11932229
Article Info
Journal
Antimicrobial agents and chemotherapy
Abbr.
Antimicrob Agents Chemother
ISSN
0066-4804
DOI
10.1128/AAC.47.6.1979-1983.2003
Published
2003-06-00
Pages
1979-83
Language
English
Region
United States
NLM ID
0315061
PMCID
PMC155823
Subset
IM
External Links
PubMed source DOI: 10.1128/AAC.47.6.1979-1983.2003 PMC Full Text View journal details
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com

Copyright © 2026.Genelibs Jinan Honghui Biotechnology Co., Ltd. 鲁ICP备20007159号-2